NEW YORK, Dec. 12, 2016 /PRNewswire/ -- American Oriental Bioengineering, Inc. (Ticker: "AOBI"), is a Nevada corporation involved in the business of developing, manufacturing and distributing a broad range of pharmaceutical and healthcare products and conducts business from Beijing, China. AOBI was de-listed from the NASDAQ in 2012 after it stopped reporting to the Securities & Exchange Commission ("SEC").
Several shareholders have spoken with Robert W. Seiden, Esq. in New York to represent a group of shareholders to enforce the rights of the U.S. shareholders for acts detrimental to the investors including gross mismanagement, failure to comply with SEC orders and others in order to get a return of capital to the investors.
If you are a current shareholder of AOBI and interested in information to consider joining in the case, please email Nathaniel Francis at the email: email@example.com or call 212.626.6709. You can also register on the website www.confidentialglobal.com under "Join Receivership Case".
SOURCE The Seiden Group